NCT02945020View on ClinicalTrials.gov

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

January 9, 2017

Study Completion Date

January 20, 2017

Conditions
Healthy
Interventions
DRUG

Dabigatran etexilate mesylate

Participants will receive dabigatran etexilate mesylate 75 mg, orally.

DRUG

Odalasvir (ODV)

Participants will receive ODV 25 mg, orally.

DRUG

Simeprevir (SMV)

Participants will receive SMV 75 mg, orally.

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02945020 - A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants | Biotech Hunter | Biotech Hunter